Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Current diagnosis of schizophrenia.~* Subject has PANSS total score ≥80, AND score of 4 or more in at least 2 of the following PANSS items at Screening and at Baseline: conceptual disorganization delusions; hallucinatory behavior; unusual thought content.~* Subjects must be able to wear a transdermal patch for 24 hours.~Exclusion Criteria:~* Subject has been diagnosed with schizophrenia less than 6 months prior to Screening Visit.~* Subject has received within 90 days of Screening Visit: electroconvulsive therapy; transcranial magnetic stimulation; vagal nerve stimulation; or other brain stimulation treatments~* Subject has experienced acute depressive symptoms within 30 days prior to Screening Visit that requires treatment with an antidepressant, as determined by the Investigator.~* Currently taking clozapine for the treatment of schizophrenia.~* Has hypothyroidism or hyperthyroidism.~* Subject is currently being treated with insulin for diabetes.~* Subject has epilepsy or history of seizures.~* Positive urine pregnancy test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low dose Asenapine maleate patch (Type: EXPERIMENTAL): Low dose asenapine maleate, transdermal patches will be compared against placebo patches.
- High dose asenapine maleate patch (Type: EXPERIMENTAL): High dose asenapine maleate, transdermal patches will be compared against placebo patches.
- Placebo transdermal patch (Type: PLACEBO_COMPARATOR): Low dose or high dose asenapine maleate transdermal patch will be compared against placebo patches

Based on this trial design, predict the completion outcome and termination type (if applicable).